Publications in collaboration with researchers from Centro Nacional de Investigaciones Oncológicas (10)

2023

  1. Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis

    Cell death & disease, Vol. 14, Núm. 8, pp. 514

2022

  1. A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL

    Molecular Therapy, Vol. 30, Núm. 2, pp. 550-563

  2. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2021

  1. Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL–Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 5, pp. 328-337.e1

2020

  1. Study protocol for a phase II, multicentre, prospective, non-randomised clinical trial to assess the safety and efficacy of infusing allogeneic activated and expanded natural killer cells as consolidation therapy for paediatric acute myeloblastic leukaemia

    BMJ Open, Vol. 10, Núm. 1

2019

  1. Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF

    Cancer Cell, Vol. 35, Núm. 4, pp. 573-587.e6

  2. NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia

    Leukemia, Vol. 33, Núm. 7, pp. 1557-1569

2018

  1. Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 115, Núm. 6, pp. E1147-E1156

2016

  1. Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency

    Stem Cell Reports, Vol. 7, Núm. 4, pp. 602-618

2015

  1. Pazopanib in pretreated advanced neuroendocrine tumors: A phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)

    Annals of Oncology, Vol. 26, Núm. 9, pp. 1987-1993